Activity of Ertapenem against Enterobacteriaceae in seven global regions-SMART 2012-2016

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
Sibylle H LobDaniel F Sahm

Abstract

Antimicrobial resistance among Enterobacteriaceae has been increasing globally especially due to extended-spectrum-β-lactamases (ESBLs), which typically necessitate the use of carbapenems for treatment of serious infections. Emerging carbapenem-resistant Enterobacteriaceae further complicate therapy. As part of the Study for Monitoring Antimicrobial Resistance Trends (SMART), this analysis examined the recent activity of a key carbapenem (ertapenem) and other important therapeutic options against Enterobacteriaceae. From 2012 to 2016, 224 hospitals in 57 countries collected up to 100 consecutive gram-negative bacilli from intra-abdominal (IAI) and 50 from urinary tract infections (UTI) per year, totaling 106,300 Enterobacteriaceae isolates. Susceptibility was determined using CLSI broth microdilution and breakpoints. Although statistically significant decreasing trends in ertapenem activity against Enterobacteriaceae were found in all regions except Middle East, the actual size of the decreases was < 3 percentage points, and susceptibility in 2015-2016 remained ca. 90% or higher, ranging from 89.5% in Asia to 97.3% in US/Canada. Of the comparators, only amikacin exceeded these results. Ertapenem was active against > 90% of isol...Continue Reading

References

Mar 11, 2005·Expert Review of Anti-infective Therapy·George G ZhanelDaryl J Hoban
May 27, 2005·The Journal of Antimicrobial Chemotherapy·Johann D D PitoutLaurent Poirel
Dec 12, 2007·Antimicrobial Agents and Chemotherapy·Christian G GiskeUNKNOWN ReAct-Action on Antibiotic Resistance
Jun 19, 2012·The Korean Journal of Internal Medicine·David M Livermore
Jun 17, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P Nordmann, L Poirel
Feb 26, 2016·The Journal of Antimicrobial Chemotherapy·Belén Gutiérrez-GutiérrezUNKNOWN REIPI/ESGBIS/INCREMENT Group
Jun 1, 2013·Journal of Global Antimicrobial Resistance·Ursula Theuretzbacher
Apr 5, 2017·The Journal of Infectious Diseases·Latania K Logan, Robert A Weinstein
Apr 12, 2017·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·James A KarlowskyDaniel F Sahm
May 26, 2017·The Journal of Antimicrobial Chemotherapy·Edward R BevanPeter M Hawkey

❮ Previous
Next ❯

Software Mentioned

SMART

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.